宁鹏1,2 徐珞1.恩替卡韦联合胸腺肽α1 治疗慢性乙型肝炎疗效研究[J].现代生物医学进展英文版,2011,11(10):1931-1933. |
恩替卡韦联合胸腺肽α1 治疗慢性乙型肝炎疗效研究 |
Curative Effect of Entecavir plus Thymosin α1 for Patientswith Chronic Hepatitis B |
|
DOI: |
中文关键词: 慢性乙型肝炎 恩替卡韦 胸腺素α1 临床效果 |
英文关键词: Chronic hepatitis B entecavir thymosin α1 clinical therapy |
基金项目: |
|
Hits: 756 |
Download times: 1088 |
中文摘要: |
目的:观察和比较恩替卡韦联合胸腺肽α1 治疗HBeAg 阳性慢性乙型肝炎的疗效。方法:选取我院58 例HBeAg 阳性慢性
乙型肝炎患者分成联合组和对照组。联合组28 例,初始同时使用恩替卡韦及胸腺肽α1 24 周,之后停胸腺肽α1 继续用恩替卡韦
至48 周。对照组30 例,单用恩替卡韦0.5mg/d,48 周。定期检测ALT 复常率,HBV DNA 转阴率,HBeAg/抗HBe 血清转换率,
肝纤维化组合,Fibroscan 评分两组在治疗结束时进行疗效评价。结果:24 周时两组ALT 复常率无差异显著性(P>0.05),联合组
和对照组HBV DNA 阴转率在24 周、48 周时均差异有显著性(P<0.05)。联合组与单用组HBeAg 血清转换率在第24 周、48 周
时,两组比较差异均有显著性(P<0.05)。肝纤维化组合各指标(HA,LN,PIIIP,Ⅳ型胶原),Fibroscan 评分两组治疗48 周后比较差
异均有显著性(P<0.05),且两组治疗前后差异联合组更显著。治疗过程中,未发现明显副作用。结论:恩替卡韦联合胸腺肽α1 治
疗HBeAg 阳性慢性乙型肝炎,安全性与耐受性良好,联合组在ALT 复常率,HBeAg 血清转换率和HBV DNA 转阴率,抗肝纤维
化的疗效上显著优于单用恩替卡韦组。 |
英文摘要: |
Objective: To observe the effect of entecavir and thymosin α1 treatment HBeAg positive chronic patitis B patients.
Methods: 58 HBeAg-positive patients with chronic hepatitis B were divided into combination group(n=28) and control group(n=30). The
combination group was treated with entecavir and thymosinα1 for 24 weeks ,and then stopping using thymosinα1 and continuing
entecavir until 48 weeks;the control group was given entecavir (0.5mg daily) for 48 weeks, regularly testing the recovery rate ofALT,
HBV DNA negative conversion rate, HBeAg/anti-HBe seroconversion rate, combination of hepatic fibrosis. Results: At 24 weeks there
were no difference in the recovery rate of ALT between the two groups (P>0.05), There were respectively significant differences
between the two group patients both HBeAg seroconversion rates and HBV DNA negative rate at 24 weeks, 48 weeks (P<0.05). The
levels of liver fibrosis indexes(HA, LN, PIIIP,Ⅳ-collagen)and fibroscan score decreased significantly after treatment for 48 weeks of two
treatment groups , The differences were statistically significant (P<0.05 ). No adverse reaction was reported during the treatment.
Conclusions: Entecavir and thymosin α1 for HBeAg positive chronic hepatitis B have a good safety and tolerability , the combination
group in the rate of ALT normalization, HBeAg seroconversion and HBV DNA negative rate, the efficacy of hepatic fibrosis is
significantly superior to the entecavir group alone. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|